Professor David Leibowitz, MD FACC Joins CardioLync Scientific Advisory Board

JERUSALEM - Dec. 21, 2021 - PRLog -- CardioLync today announced that Professor David Leibowitz, MD FACC has joined its Scientific Advisory Board.

CardioLync's platform for interpreting, reporting, and engaging with patients for diagnostic imaging and communication improves care for chronic disease patients through effective interdisciplinary coordination.

Professor Leibowitz, Director of the Echocardiography Unit in the Cardiovascular Disease department at Hadassah-Hebrew University Medical Center in Mount Scopus, Jerusalem, is a pioneer in cutting edge diagnoses and treatments of cardiovascular disease. In addition to his clinical work treating thousands of patients, he has authored and co-authored over 120 publications.  Regarding CardioLync, Professor Leibowitz said "in principle it would be a great service to directly see study images via the web and be able to communicate efficiently with other medical providers ", and that he is "Happy to be part of this exciting project and looking forward to a fruitful collaboration".

Hadassah Hebrew-University Medical Center is recognized worldwide as a leader in cardiac care, and receives requests for consultations on both a national and international level.  CardioLync will enable Professor Leibowitz and other Hadassah medical professionals to access and interpret diagnostic data including native images, on studies performed and data generated outside of the Hadassah hospital ecosystem. The use of CardioLync's systems are particularly crucial now in view of the increased need for telemedicine services given the challenges of the COVID 19 era that have alerted the world to the dual needs for out of hospital treatment and for providing care to chronic disease patients who may skip treatment for fear of exposure.

Jeremy Kagan, CEO of CardioLync said, "The CardioLync team is both proud to have earned the trust of Professor Leibowitz and to be accepted by Hadassah for pilot; and humbled by the responsibility that comes with working with a world leading medical institution.  We have been progressing towards this goal for years- developing an innovative technology and unique interface that saves doctors 40% in time spent on interpreting and reporting on ECHOs and other cardiographic studies.  Our team is ready and up for the challenge."

About CardioLync
CardioLync facilitates a unified view of a chronic disease patient's condition across specialties, across hospitals, and across regions. CardioLync's pioneering Diagnostic Modality Interface Portal (DMIP) is a web accessible secure software technology which enables fluent communication and native image access at the point of care among different medical specialists, imaging technicians, nurses, and patients; improving workflow efficiency and coordinated clinical decision making among these stakeholders; while providing patient control and engagement.

Diagnostic Modality Interface Portal and DMIP are trademarks of CardioLync, Inc.

https://www.cardiolync.com/